The world’s first oral treatment for AMD.

We are bringing your eyes back to their youthfulness.

The MHRA in the United Kingdom has approved a Clinical Trial Authorization (CTA) for an oral treatment for Age-related Macular Degeneration (AMD) to proceed to a Phase 2b clinical trial.

AltRegen is a biomedical company dedicated to developing a treatment for AMD and specializes in the biophysical aspects of Bruch’s membrane of the eye. We are working with numerous internationally respected world experts on AMD.

Our research elucidated the underlying mechanisms in AMD allowing us to formulate a treatment for this disease. As a consequence, we now hold worldwide patents and formulations for the prevention and treatment of AMD.

This is the only company to have developed a formula for removing the age-related accumulation of debris from Bruch’s membrane.AltRegen® formulation improves transport across Bruch’s membrane to restore the deficits in dark adaptation occurring in elderly people and AMD patients.

This means that the AltRegen® formulation improves the structure and function of Bruch’s membrane enabling the maintenance of good vision. Our teams have worked on this important project for many years and will not give up until we establish a treatment to help the patients.

We are happy to give you the opportunity to maintain good vision and prevent blindness allowing you a better quality of life.

We will help to maintain your eyesight to enjoy life with your loved ones.

Learn more about AMD

Everything you need to know about Age-related Macular Degeneration.

제10기 임시주주총회 공고

  1. 기준일(권리주주확정일): 2025년 9월 16일
  2. 임시주주총회 일시

    - 2025년 10월 2일 (목) 오전 11시

  3. 장소

    - 서울시 금천구 벚꽃로 244, 12층 1201호 회의실

  4. 회의목적사항

    가. 부의 안건

    1. 제1호 의안: 사내이사 선임의 건
    2. 제2호 의안: 감사 선임의 건
    3. 제3호 의안: 주식매수선택권(스톡옵션) 부여의 건

 임시주주총회 시간, 장소, 안건은 향후 이사회에서 변경될 수 있습니다.

2025년 9월 1일
주식회사 알트리젠